NextCODE Buy Boosts WuXi’s Genomics Expertise
This article was originally published in PharmAsia News
WuXi PharmaTech has acquired the genomic analysis company NextCODE Health for $65 million in cash. The Shanghai-based R&D technology firm plans to merge the NextCODE Health business into its own genome center, creating a new company to be known as WuXi NextCODE Genomics.
You may also be interested in...
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.